Vanguard Group’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $134M | Sell |
|
|||||
|
2025
Q2 | $129M | Buy |
|
|||||
|
2025
Q1 | $130M | Sell |
|
|||||
|
2024
Q4 | $99.2M | Sell |
|
|||||
|
2024
Q3 | $79.7M | Buy |
|
|||||
|
2024
Q2 | $145M | Sell |
|
|||||
|
2024
Q1 | $149M | Buy |
|
|||||
|
2023
Q4 | $172M | Buy |
|
|||||
|
2023
Q3 | $152M | Buy |
|
|||||
|
2023
Q2 | $198M | Sell |
|
|||||
|
2023
Q1 | $203M | Buy |
|
|||||
|
2022
Q4 | $190M | Buy |
|
|||||
|
2022
Q3 | $259M | Buy |
|
|||||
|
2022
Q2 | $281M | Buy |
|
|||||
|
2022
Q1 | $358M | Buy |
|
|||||
|
2021
Q4 | $281M | Sell |
|
|||||
|
2021
Q3 | $267M | Buy |
|
|||||
|
2021
Q2 | $287M | Buy |
|
|||||
|
2021
Q1 | $316M | Buy |
|
|||||
|
2020
Q4 | $261M | Buy |
|
|||||
|
2020
Q3 | $258M | Sell |
|
|||||
|
2020
Q2 | $230M | Buy |
|
|||||
|
2020
Q1 | $146M | Buy |
|
|||||
|
2019
Q4 | $197M | Sell |
|
|||||
|
2019
Q3 | $169M | Buy |
|
|||||
|
2019
Q2 | $171M | Buy |
|
|||||
|
2019
Q1 | $149M | Buy |
|
|||||
|
2018
Q4 | $163M | Buy |
|
|||||
|
2018
Q3 | $179M | Buy |
|
|||||
|
2018
Q2 | $109M | Buy |
|
|||||
|
2018
Q1 | $102M | Buy |
|
|||||
|
2017
Q4 | $149M | Buy |
|
|||||
|
2017
Q3 | $119M | Buy |
|
|||||
|
2017
Q2 | $147M | Buy |
|
|||||
|
2017
Q1 | $130M | Buy |
|
|||||
|
2016
Q4 | $88.7M | Buy |
|
|||||
|
2016
Q3 | $91.3M | Buy |
|
|||||
|
2016
Q2 | $87.3M | Buy |
|
|||||
|
2016
Q1 | $134M | Buy |
|
|||||
|
2015
Q4 | $190M | Buy |
|
|||||
|
2015
Q3 | $98.5M | Buy |
|
|||||
|
2015
Q2 | $164M | Buy |
|
|||||
|
2015
Q1 | $199M | Buy |
|
|||||
|
2014
Q4 | $189M | Buy |
|
|||||
|
2014
Q3 | $203M | Buy |
|
|||||
|
2014
Q2 | $191M | Buy |
|
|||||
|
2014
Q1 | $137M | Buy |
|
|||||
|
2013
Q4 | $104M | Buy |
|
|||||
|
2013
Q3 | $62.4M | Buy |
|
|||||
|
2013
Q2 | $22.2M | Buy |
|